AIM: To assess the expression and prognostic value of nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) in gastric cancer, and its correlation with vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). METHODS: Tumor and adjacent tissues were obtained from 123 patients who underwent radical surgery for gastric cancer at Renmin Hospital of Wuhan University from 2008-2009. The expression of NOX2, VEGF, EGFR and CD68 in tumor tissues was detected by immunohistochemistry. The expression of NOX2 in gastric cancer and adjacent tissues was detected by Western blot analysis. Spearman(')s correlation was performed to elucidate the relationship of NOX2 with VEGF and EGFR. The Kaplan-Meier method was used to calculate survival time, and the log-rank test was used to evaluate differences in survival. Cox's proportional hazards regression model was applied in a stepwise manner to analyze the independent prognostic factors. RESULTS: NOX2 exhibited positive expression in 47.2% (58/123) of the gastric cancer tissues. Western blot analysis revealed that NOX2 was up-regulated in tumor tissues compared to the adjacent tissue [39.0% (48/123)]. Immunohistochemistry staining revealed that CD68, which is a specific marker of macrophages, and NOX expression presented a similar localization and staining intensity. The expression of NOX2 was positively correlated with that of VEGF and EGFR. Comparison of the 5-year survival rates of the NOX2 positive and NOX2 negative groups showed that the NOX2 positive group presented a poor prognosis. CONCLUSION: NOX2 positively correlates with the levels of VEGF and EGFR. NOX2 may be used as a new biomarker and a potential therapeutic target for gastric cancer.
AIM: To assess the expression and prognostic value of nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) in gastric cancer, and its correlation with vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). METHODS:Tumor and adjacent tissues were obtained from 123 patients who underwent radical surgery for gastric cancer at Renmin Hospital of Wuhan University from 2008-2009. The expression of NOX2, VEGF, EGFR and CD68 in tumor tissues was detected by immunohistochemistry. The expression of NOX2 in gastric cancer and adjacent tissues was detected by Western blot analysis. Spearman(')s correlation was performed to elucidate the relationship of NOX2 with VEGF and EGFR. The Kaplan-Meier method was used to calculate survival time, and the log-rank test was used to evaluate differences in survival. Cox's proportional hazards regression model was applied in a stepwise manner to analyze the independent prognostic factors. RESULTS:NOX2 exhibited positive expression in 47.2% (58/123) of the gastric cancer tissues. Western blot analysis revealed that NOX2 was up-regulated in tumor tissues compared to the adjacent tissue [39.0% (48/123)]. Immunohistochemistry staining revealed that CD68, which is a specific marker of macrophages, and NOX expression presented a similar localization and staining intensity. The expression of NOX2 was positively correlated with that of VEGF and EGFR. Comparison of the 5-year survival rates of the NOX2 positive and NOX2 negative groups showed that the NOX2 positive group presented a poor prognosis. CONCLUSION:NOX2 positively correlates with the levels of VEGF and EGFR. NOX2 may be used as a new biomarker and a potential therapeutic target for gastric cancer.
Authors: Masuko Ushio-Fukai; Yan Tang; Tohru Fukai; Sergey I Dikalov; Yuxian Ma; Mitsuaki Fujimoto; Mark T Quinn; Patrick J Pagano; Chad Johnson; R Wayne Alexander Journal: Circ Res Date: 2002-12-13 Impact factor: 17.367
Authors: Shakil A Khan; Jayasri Nanduri; Guoxiang Yuan; Brian Kinsman; Ganesh K Kumar; Joy Joseph; Balaraman Kalyanaraman; Nanduri R Prabhakar Journal: Antioxid Redox Signal Date: 2010-10-19 Impact factor: 8.401
Authors: Sanja Coso; Ian Harrison; Craig B Harrison; Antony Vinh; Christopher G Sobey; Grant R Drummond; Elizabeth D Williams; Stavros Selemidis Journal: Antioxid Redox Signal Date: 2012-03-23 Impact factor: 8.401
Authors: Hitesh Peshavariya; Gregory J Dusting; Fan Jiang; Lesley R Halmos; Christopher G Sobey; Grant R Drummond; Stavros Selemidis Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2009-04-01 Impact factor: 3.000
Authors: Andrew C Little; Arvis Sulovari; Karamatullah Danyal; David E Heppner; David J Seward; Albert van der Vliet Journal: Free Radic Biol Med Date: 2017-05-31 Impact factor: 7.376
Authors: Guadalupe S López-Álvarez; Tomasz K Wojdacz; Claudia M García-Cuellar; Hugo C Monroy-Ramírez; Miguel A Rodríguez-Segura; Ruth A Pacheco-Rivera; Carlos A Valencia-Antúnez; Nancy Cervantes-Anaya; Ernesto Soto-Reyes; Verónica R Vásquez-Garzón; Yesennia Sánchez-Pérez; Saúl Villa-Treviño Journal: Biol Open Date: 2017-01-15 Impact factor: 2.422